Laboratory Testing for a 27-Year-Old Male with Suspected IBS-D
In a 27-year-old male with suspected IBS-D and no alarm features, order a focused panel consisting of: CBC, IgA tissue transglutaminase with total IgA, fecal calprotectin, stool Giardia antigen test, and fecal occult blood test. 1
Core Baseline Laboratory Panel
The following tests should be obtained in all patients with suspected IBS-D before confirming the diagnosis:
Complete blood count (CBC) – Screens for anemia and inflammatory changes that would suggest organic disease rather than functional IBS 1
IgA tissue transglutaminase (tTG-IgA) with total IgA level – Celiac disease must be excluded in all patients with IBS symptoms regardless of predominant stool pattern, as it mimics IBS-D with >90% sensitivity 1, 2
- If total IgA is low or absent (occurs in 1-3% of celiac patients), order IgG deamidated gliadin peptide instead 2
Fecal calprotectin – Values <50 µg/g exclude inflammatory bowel disease with 97% specificity; values >200-250 µg/g mandate colonoscopy 1, 3
- This test is specifically recommended for patients <45 years with diarrhea to avoid missing IBD 1
Stool Giardia antigen test – Giardia is the most common parasitic cause of chronic diarrhea (54% of identified parasites), and enzyme immunoassay has >95% sensitivity and specificity 1, 4
Fecal occult blood test – Screens for occult gastrointestinal bleeding 1
Tests That Are NOT Recommended
Do not order C-reactive protein (CRP) or ESR as routine screening tests – The American Gastroenterological Association advises against these because they have poor diagnostic accuracy for IBD screening, and approximately 20% of active Crohn's disease patients have normal CRP 1
Do not order ova and parasite examination unless the patient has travel history to or recent immigration from endemic areas 1
Do not order hydrogen breath testing for small intestinal bacterial overgrowth or lactose malabsorption as part of initial evaluation 1, 5
Do not order colonoscopy in a patient <45 years with typical IBS-D symptoms and no alarm features – this is not cost-effective and delays appropriate care 1, 6
Alarm Features That Would Change the Testing Strategy
If any of the following are present, proceed directly to colonoscopy rather than limited testing 1:
- Age ≥45 years at symptom onset
- Unintentional weight loss
- Rectal bleeding or visible blood in stool
- Anemia on CBC
- Nocturnal diarrhea that awakens the patient from sleep
- Fever
- Family history of inflammatory bowel disease or colorectal cancer
Additional Testing If Initial Therapy Fails
Bile acid diarrhea testing (SeHCAT scan or serum 7α-hydroxy-4-cholesten-3-one) should be considered if the patient does not respond to initial IBS-D treatment, as 25-33% of patients initially classified as IBS-D actually have bile acid diarrhea 1, 5
Lactose breath testing may be considered only if the patient consumes >0.5 pint (280 mL) of milk daily, especially in high-risk ethnic groups 1
Common Pitfalls to Avoid
Over-testing young patients with typical symptoms leads to increased costs, delays diagnosis, and raises patient anxiety without improving outcomes 1, 7
Ordering advanced serologic panels (such as C1 esterase inhibitor, MEFV gene, porphobilinogen, anti-dsDNA, or heavy metal screening) is inappropriate in typical IBS – one study found only 2.1% positive rate with $39,007 spent on inappropriate testing 7
Relying on patient-reported food intolerances without objective testing often leads to unnecessary dietary restrictions 1
Assuming normal CRP rules out IBD is unsafe, as one-fifth of active Crohn's patients have normal inflammatory markers 1